Abstracts tagged "Heart disease"

Abstract Number: 0679 • ACR Convergence 2022
Outcomes of Antiphospholipid Antibody Syndrome and Acute Coronary Syndrome: Analysis of National Inpatient Sample 
Faria Sami, Dennis Kumi and Shilpa Arora, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL
Background/Purpose: Antiphospholipid antibody syndrome (APLS) is strongly associated with the risk of cardiovascular events including acute coronary syndrome (ACS). However, there is limited data on…
Abstract Number: 1623 • ACR Convergence 2022
Combined Single-Cell, Bulk RNA Sequencing and Proteomics Analysis Reveals New Candidate Targets Involved in Myocardial Fibrogenesis
Ievgeniia Kocherova¹, Elena Pachera², Daria Nurzynska³, Franca Di Meglio³, Oliver Distler⁴, Przemysław Błyszczuk² and Gabriela Kania², ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ³Department of Public Health, University of Naples "Federico II", Naples, Italy, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland
Background/Purpose: Inflammatory dilated cardiomyopathy (iDCM) often leads to heart failure (HF), which is the main cause of cardiac mortality in patients with systemic autoimmune diseases.…
Abstract Number: 0741 • ACR Convergence 2022
Prescribing Patterns of SGLT2 Inhibitors for Patients with Autoimmune Rheumatic Disease
Emily G Oakes¹, Jack Ellrodt¹, May Choi², Hongshu Guan¹ and Karen Costenbader¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada
Background/Purpose: Sodium-glucose co-transporter 2 inhibitors (SGLT2i, dapagliflozin, canagliflozin, and empagliflozin) are a class of oral hypoglycemic medication for management of Type II diabetes mellitus (T2D),…
Abstract Number: 1789 • ACR Convergence 2022
Gout in Heart Failure Patients with Left Ventricular Assist Device Therapy in a Tertiary Academic Hospital
Aakriti Arora¹, Lakshmi Jayaram², TEFERA ESHETU³ and FLORINA CONSTANTINESCU³, ¹MedStar Washington Hospital Center, Georgetown University, Washington, DC, ²McGaw Medical Center, Northwestern University, Chicago, IL, ³MedStar Washington Hospital Center, Washington, DC
Background/Purpose: Gout is one of the most common inflammatory joint diseases and is a disabling complication in patients with heart failure. Patients with gout and…
Abstract Number: 0805 • ACR Convergence 2022
Rheumatic Fever and Streptococcal Cutaneous Infection: A Case-control Study in the Loyalty Islands, New Caledonia
Quentin AMIC-DESVAUD¹, Olivier MAILLARD², Sylvia IACOBELLI³, Thomas BARDIN⁴ and Yves-Marie DUCROT⁵, ¹Province des îles Loyauté, Lifou, New Caledonia, ²Centre Hospitalier Universitaire de la Reunion, Saint-Denis, France, ³Centre Hospitalier Universitaire, Saint Dénis de la Réunion, France, ⁴Université de Paris, Paris, France, ⁵Province des îles Loyauté, We, Lifou Island, New Caledonia
Background/Purpose: Acute Rheumatic Fever (ARF) and Rheumatic Heart Disease (RHD) remain major public health problems in the South Pacific. Triggering by group A beta hemolytic…
Abstract Number: 1815 • ACR Convergence 2022
Consistent Colchicine Use Is Associated with Decreased Major Adverse Cardiovascular Events in Patients with Gout and Established Cardiovascular Disease
Gary Ho¹, Michael Toprover², Daria Crittenden³, binita Shah⁴ and Michael Pillinger⁵, ¹New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, ²Division of Rheumatology, New York University Grossman School of Medicine and Rheumatology Section, New York Harbor Health Care System, New York Campus of the U.S. Department of Veterans Affairs, New York, NY, ³CymaBay Therapeutics, New York University Grossman School of Medicine, Newark, CA, ⁴New York University Grossman School of Medicine, VA New York Harbor Health Care System, New York, NY, ⁵NYU Grossman School of Medicine, New York, NY
Background/Purpose: Patients with gout are more likely than those without to have traditional risk factors for cardiovascular (CV) disease. Furthermore, the chronic, low-level inflammation experienced…
Abstract Number: 0896 • ACR Convergence 2022
Screening of Lipids in Patients with Rheumatoid Arthritis: Academic Rheumatology Practice Quality Improvement Analysis
Sukhraj Singh¹ and Gurjit S. Kaeley², ¹University of Florida-Jacksonville, Jacksonville, FL, ²UF COM-J, Ponte Vedra Beach, FL
Background/Purpose: Patients with Rheumatoid Arthritis (RA) have 50% increased risk of cardiovascular disease (CVD) mortality compared with the general population. The American College of Cardiology/American…
Abstract Number: 1871 • ACR Convergence 2022
Hospitalization Outcomes for Acute Myocardial Infraction and Acute Heart Failure in Patients with Idiopathic Inflammatory Myopathies (IIM) from 2016-2019 National Inpatient Sample (NIS)
Zi Ying Li¹, Siyi Huang², Kevin Xi³, Deepan Dalal⁴ and Anthony Reginato⁵, ¹Roger Williams Medical Center, Providence, RI, ²UCSF Fresno, Fresno, CA, ³Brown University, Providence, ⁴Brown University School of Medicine, Providence, RI, ⁵Brown University, Providence, RI
Background/Purpose: Cardiovascular disease was encountered in 15% of hospital admission from 2016-2017 for patients with idiopathic inflammatory myopathies (IIM) based on the National Inpatient Sample…
Abstract Number: 0898 • ACR Convergence 2022
Risk of Aortic Stenosis and Undergoing Aortic Valve Replacement in Rheumatoid Arthritis: An Underrecognized Cardiovascular Complication
Tate Johnson¹, Yangyuna Yang², Chetaj Mahabir², Andrew Goldsweig², Punyasha Roul³, Joshua Baker⁴, Brian Sauer⁵, Grant Cannon⁶, Ted Mikuls⁷ and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Retired, Salt Lake City, UT, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Valvular carditis is reported as a rare extra-articular manifestation of rheumatoid arthritis (RA). In animal models with coexistent inflammatory arthritis, pro-inflammatory infiltrates of T…
Abstract Number: 1963 • ACR Convergence 2022
Lipid Screening and Statin Use in Rheumatoid Arthritis Patients in an Underserved Population
Colleen O'Neill¹ and Veena Patel², ¹Dell Medical School - UTHealth Austin, Austin, TX, ²Dell Medical School - UT Health Austin, Austin, TX
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of atherosclerotic cardiovascular disease (ASCVD) compared to the general population and RA is considered a…
Abstract Number: 0981 • ACR Convergence 2022
QTc Prolongation in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients Treated with Hydroxychloroquine – Preliminary Results from a Single Center Study
Tanmayee Bichile¹, Susan Manzi² and Tarun Sharma³, ¹Allegheny Health Network, Gibsonia, PA, ²Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, ³Allegheny Health Network, Pittsburgh, PA
Background/Purpose: The effect of hydroxychloroquine (HCQ) on QTc interval in patients with rheumatic diseases is under scrutiny since the COVID-19 pandemic, however studies have shown…
Abstract Number: 2169 • ACR Convergence 2022
Cardiac Rhythm and Conduction Abnormalities in Systemic Sclerosis-meta-analysis
Drashti Antala¹, Angkawipa Trongtorsak¹, Qingqing Meng¹, Akshaya Ramachandran¹, Aanshi Patel², Pabitra Adhikari¹, Prasun Pudasainee¹ and Krutarth Pandya³, ¹Ascension Saint Francis hospital, Evanston, IL, ²B.J. Medical College, Ahmedabad, Ahmedabad, India, ³Trumbull Regional Medical Centre, Warren, OH
Background/Purpose: Systemic sclerosis( SSc) can primarily cause repeated focal ischaemic insults in the myocardium and result in irreversible myocardial fibrosis. Myocardial involvement, when becomes clinically…
Abstract Number: 0983 • ACR Convergence 2022
Hydroxychloroquine Use and Heart Failure with Preserved Ejection Fraction in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Jake Altier, Fedelis Mutiso, Paul Nietert, Sheldon Litwin and Jim Oates, Medical University of South Carolina, Charleston, SC
Background/Purpose: Initially used as an antimalarial, hydroxychloroquine (HCQ) is standard of care treatment for systemic lupus erythematosus (SLE) and is used as monotherapy or adjunct…
Abstract Number: 1046 • ACR Convergence 2022
Scleroderma Heart Disease
Mohamed Talaat¹, Vivien Hsu² and Daniel Shindler³, ¹Rutgers Robert Wood Johnson University Hospital, North Brunswick, NJ, ²Rutgers-RWJ Medical School, South Plainfield, NJ, ³Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ
Background/Purpose: Scleroderma heart involvement (SHI) is the 3rd leading cause of death in systemic sclerosis (SSc) [1] following interstitial lung disease (ILD) & pulmonary arterial…
Abstract Number: 1049 • ACR Convergence 2022
Risk Stratification of Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension in EUSTAR Using the Current and New Proposed Criteria
Hilde Jenssen Bjørkekjær¹, cosimo bruni², PATRICIA E CARREIRA³, Paolo Airò⁴, CARMEN PILAR SIMEON⁵, Marie-Elise Truchetet⁶, Alessandro Giollo⁷, Alexandra Balbir-Gurman⁸, Mickaël MARTIN⁹, Chris Denton¹⁰, Armando Gabrielli¹¹, Håvard Fretheim¹², Imon Barua¹², Helle Bitter¹³, Øyvind Midtvedt¹², Kaspar Broch¹⁴, Arne Andreassen¹², Yoshiya Tanaka¹⁵, Gabriela Riemekasten¹⁶, Ulf Müller-Ladner¹⁷, Marco Matucci-Cerinic², Ivan Castellvi¹⁸, Elise Siegert¹⁹, Eric Hachulla²⁰, Oliver Distler²¹ and Anna-Maria Hoffmann-Vold¹², ¹Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, Kristiansand, Norway, ²University of Florence, Florence, Italy, ³HOSPITAL 12 DE OCTUBRE, Madrid, Spain, ⁴Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy, ⁵Hospital Vall D'Hebron, Barcelona, Spain, ⁶CHU de Bordeaux, Bordeaux, France, ⁷Rheumatology Section, Department of Medicine, University of Verona, Italy, Verona, Italy, ⁸Rheumatology Institute, Rambam Health Care Campus, Haifa, Israel, ⁹Poitiers's Universatory Hospital, Department of Internal Medicine, Poitiers, France, Mignaloux-Beauvoir, France, ¹⁰University College London, London, United Kingdom, ¹¹Università Politecnica delle Marche, Ancona, Italy, ¹²Oslo University Hospital, Oslo, Norway, ¹³Sorlandet sykehus, Kristiansand, Norway, ¹⁴Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, Oslo, Norway, ¹⁵University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ¹⁶University Clinic Schleswit-Holstein (UKSH), Luebeck, Germany, ¹⁷JLU Campus KK, Bad Nauheim, Germany, ¹⁸Hospital Universitari de la Santa Creu i Sant Pau, Vilafranca del Pened, Spain, ¹⁹Charité Hospital, Berlin, Germany, ²⁰University of Lille, LILLE, France, ²¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major clinical challenge in systemic sclerosis (SSc). A new definition for precapillary PH is proposed. Risk stratification is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].